Compare McDonald's Corp (MCD) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McDonald's Corp vs Neurocrine Biosciences Inc — how do they compare? McDonald's Corp trades at $264.57 (market cap $190.16B), while Neurocrine Biosciences Inc trades at $177.96 (market cap $17.40B). The key difference: McDonald's Corp is far larger — about 10.9× Neurocrine Biosciences Inc's market cap, and McDonald's Corp pays a 2.78% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MCD | NBIX | |
|---|---|---|
Market Cap | $190.16B | $17.40B |
Volume | 2,230,036 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $180.55 |
52-Week Low | $264.54 | $123.10 |
Enterprise Value | $243.87B | $16.49B |
Dividend Yield | 2.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $267.71, down 2.1% on the day, with a bearish technical signal driven by moving averages. The company reported steady revenue growth to $26.89 billion in 2025 and a net income margin of 31.62%, though Q2 2026 earnings are pending. Recent news highlights a new 'McDonald's NEXT' strategy focusing on automation and menu improvements to boost competitiveness.
The stock presents a buying opportunity with a consensus price target of $329, implying 23% upside, supported by strong analyst sentiment (58% buy ratings). Risks include inflationary pressures on franchisee margins and high long-term debt of $38.42 billion. Earnings execution and strategy rollout will be key for near-term performance.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% with strong bullish momentum. Recent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, underscore robust growth. The stock shows bullish technical signals with support at $170 and resistance at $173. Revenue growth accelerated to $2.86 billion in 2025, with net income margin improving to 21.55% in 2026 projections. Positive news highlights pipeline advancements and the Soleno acquisition.
Outlook remains positive with a consensus price target of $196.08, implying 13% upside. Key opportunities include sustained earnings growth and pipeline expansion, while risks involve clinical trial outcomes and competitive pressures. Institutional sentiment is strongly bullish with 86% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
